Among the 1,588 advanced non-squamous NSCLC patients enrolled in the Italian Expanded Access Program of second line nivolumab, 210 patients were assessed for BRAF mutations, and 11 patients (5%) were found to be positive. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.